A detailed history of Marshall Wace, LLP transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 28,187 shares of PDSB stock, worth $54,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,187
Holding current value
$54,682
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.93 - $4.23 $82,587 - $119,231
28,187 New
28,187 $107,000
Q1 2024

May 15, 2024

BUY
$3.85 - $6.59 $158,700 - $271,646
41,221 New
41,221 $163,000
Q3 2023

Nov 14, 2023

SELL
$4.8 - $6.4 $21,240 - $28,320
-4,425 Reduced 6.04%
68,795 $347,000
Q2 2023

Aug 14, 2023

SELL
$5.03 - $9.9 $330,913 - $651,301
-65,788 Reduced 47.33%
73,220 $368,000
Q1 2023

May 15, 2023

BUY
$5.68 - $11.99 $587,175 - $1.24 Million
103,376 Added 290.12%
139,008 $854,000
Q4 2022

Feb 14, 2023

BUY
$3.28 - $13.2 $26,351 - $106,048
8,034 Added 29.11%
35,632 $470,000
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.79 $145,966 - $284,561
-49,147 Reduced 64.04%
27,598 $82,000
Q2 2022

Aug 15, 2022

SELL
$3.05 - $6.68 $285,888 - $626,143
-93,734 Reduced 54.98%
76,745 $281,000
Q1 2022

May 16, 2022

BUY
$4.78 - $8.43 $485,409 - $856,066
101,550 Added 147.33%
170,479 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $83,466 - $154,348
10,756 Added 18.49%
68,929 $557,000
Q3 2021

Nov 15, 2021

BUY
$9.33 - $17.08 $542,754 - $993,594
58,173 New
58,173 $867,000
Q2 2021

Aug 13, 2021

SELL
$4.35 - $12.86 $192,409 - $568,823
-44,232 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.28 - $6.81 $100,848 - $301,219
44,232 New
44,232 $201,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $55.2M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.